News

Cardio Diagnostics Holdings, Inc. to Showcase Enhanced PrecisionCHD™, Actionable Clinical Intelligence™ and New Clinical Advancements at the American College of Cardiology's 74th Annual Scientific Session

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its growing portfolio of advanced cardiovascular solutions at the ACC's 74th Annual Scientific Session & Expo.

03/26/2025

Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced that the Company has partnered with seven new provider organizations.

02/04/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Cardio Diagnostics Holdings, Inc. (CDIO) a buy, sell, or hold?

Cardio Diagnostics Holdings, Inc. (CDIO) can sell. Click on Rating Page for detail.

What is Cardio Diagnostics Holdings, Inc.'s stock price?

The price of Cardio Diagnostics Holdings, Inc. (CDIO) is 0.2131 and it was updated on 2025-05-08 13:00:21.

Is Cardio Diagnostics Holdings, Inc. (CDIO) overvalued or undervalued?

Currently Cardio Diagnostics Holdings, Inc. (CDIO) is in undervalued.

News

From:

To:

News
Cardio Diagnostics Holdings, Inc. Receives Final Medicare Pricing Determination from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced their PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from CMS. Mon, Dec. 16, 2024
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from CMS. Tue, Oct. 01, 2024
Cardio Diagnostics Announces It's Exhibiting at the 2024 Onsite Employee Health Clinics Forum CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum. Tue, Jun. 25, 2024
Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit. Mon, Jun. 10, 2024
Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services' (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the MolDx program. Tue, May. 21, 2024

SEC Filings

SEC Filings
Cardio Diagnostics Holdings, Inc. (CDIO) - S-8 SEC Filings 04/08/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 04/01/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 03/25/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-K - Current report SEC Filings 03/20/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - 3 SEC Filings 03/13/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 02/21/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - EFFECT SEC Filings 02/18/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B5 SEC Filings 02/14/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - S-3 SEC Filings 02/07/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - 3 SEC Filings 02/05/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 01/15/2025
Cardio Diagnostics Holdings, Inc. (CDIO) - EFFECT SEC Filings 12/04/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 12/04/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 12/03/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - S-1 SEC Filings 11/22/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 11/18/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-Q - Quarterly Report SEC Filings 11/13/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 10/10/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4/A SEC Filings 10/09/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4/A SEC Filings 10/08/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4/A SEC Filings 10/07/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - DEFA14A SEC Filings 10/04/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - DEF 14A SEC Filings 10/04/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - ARS SEC Filings 09/25/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - PRE 14A SEC Filings 09/23/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4/A SEC Filings 09/23/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 09/10/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 09/09/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - EFFECT SEC Filings 09/06/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - POS AM SEC Filings 08/30/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-Q - Quarterly Report SEC Filings 08/12/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 07/02/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 06/07/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-Q - Quarterly Report SEC Filings 05/15/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - SC 13G/A SEC Filings 05/08/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - S-8 SEC Filings 04/26/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 04/08/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 04/02/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 04/02/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-K - Current report SEC Filings 04/01/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 02/21/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - D SEC Filings 02/06/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 02/05/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - EFFECT SEC Filings 02/02/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - SC 13G SEC Filings 02/02/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 02/02/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 02/01/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B5 SEC Filings 02/01/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - DEL AM SEC Filings 01/29/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - S-3 SEC Filings 01/26/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 01/04/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 3 SEC Filings 01/04/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4/A SEC Filings 01/02/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 01/02/2024
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 12/19/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 12/06/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - DEFA14A SEC Filings 11/22/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 11/22/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-Q - Quarterly Report SEC Filings 11/13/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4/A SEC Filings 11/03/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 11/03/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - DEF 14A SEC Filings 10/27/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - PRE 14A SEC Filings 10/12/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4/A SEC Filings 10/04/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 10/04/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 10/03/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 09/25/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K/A - Current report SEC Filings 09/14/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 09/11/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 09/08/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 09/05/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-Q - Quarterly Report SEC Filings 08/14/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 07/05/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - SC 13D/A SEC Filings 06/28/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4/A SEC Filings 06/27/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 06/26/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 06/22/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 4 SEC Filings 06/21/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K/A - Current report SEC Filings 06/05/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 05/30/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 05/16/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 05/15/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-Q - Quarterly Report SEC Filings 05/15/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - DEF 14A SEC Filings 05/03/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - EFFECT SEC Filings 05/01/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 05/01/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - POS AM SEC Filings 04/24/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - EFFECT SEC Filings 04/12/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 04/11/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - PRE 14A SEC Filings 04/07/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - S-1 SEC Filings 04/05/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 03/31/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-K - Current report SEC Filings 03/31/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - S-8 SEC Filings 03/22/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 03/13/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - SC 13G/A SEC Filings 02/08/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - SC 13G/A SEC Filings 02/06/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - EFFECT SEC Filings 01/25/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 01/25/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - S-1/A SEC Filings 01/13/2023
Cardio Diagnostics Holdings, Inc. (CDIO) - S-1 SEC Filings 12/12/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 11/10/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-Q - Quarterly Report SEC Filings 11/07/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - SC 13D SEC Filings 11/04/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - SC 13D SEC Filings 11/03/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 10/31/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - SC 13G/A SEC Filings 10/28/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 25-NSE SEC Filings 10/26/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 425 SEC Filings 10/11/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - SEC STAFF LETTER SEC Filings 10/07/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 424B3 SEC Filings 10/07/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - S-4/A SEC Filings 10/05/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - CORRESP SEC Filings 10/05/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - S-4/A SEC Filings 10/04/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - CORRESP SEC Filings 10/03/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - UPLOAD SEC Filings 09/30/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 09/23/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 425 SEC Filings 09/23/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 09/21/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 425 SEC Filings 09/21/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - S-4/A SEC Filings 09/15/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - CORRESP SEC Filings 09/15/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 09/15/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 425 SEC Filings 09/15/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - UPLOAD SEC Filings 09/09/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 08/26/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 425 SEC Filings 08/26/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 8-K - Current report SEC Filings 08/25/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 425 SEC Filings 08/25/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - S-4/A SEC Filings 08/23/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - CORRESP SEC Filings 08/23/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 10-Q - Quarterly Report SEC Filings 08/10/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - UPLOAD SEC Filings 08/08/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - SEC STAFF LETTER SEC Filings 08/04/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - S-4/A SEC Filings 07/27/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - AW SEC Filings 07/27/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - S-4/A SEC Filings 07/25/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - CORRESP SEC Filings 07/25/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - UPLOAD SEC Filings 07/05/2022
Cardio Diagnostics Holdings, Inc. (CDIO) - 425 SEC Filings 05/31/2022

Press Releases

StockPrice Release
Cardio diagnostics holdings, inc. to showcase enhanced precisionchd™, actionable clinical intelligence™ and new clinical advancements at the american college of cardiology's 74th annual scientific session 03/26/2025
Cardio diagnostics expands the reach of its ai-driven precision cardiovascular medicine tests by partnering with seven new provider organizations 02/04/2025
Cardio diagnostics holdings, inc. receives final medicare pricing determination from centers for medicare and medicaid services (cms) for ai-powered cardiovascular tests 12/16/2024
Cardio diagnostics holdings, inc. receives preliminary medicare pricing from centers for medicare and medicaid services (cms) for ai-powered cardiovascular tests 10/01/2024
Cardio diagnostics announces it's exhibiting at the 2024 onsite employee health clinics forum 06/25/2024
Cardio diagnostics holdings, inc. achieves soc 2 type i compliance certification for security and confidentiality 06/10/2024
Cardio diagnostics to participate in the centers for medicare and medicaid services' (cms) clinical laboratory fee schedule (clfs) annual meeting to secure medicare payment for its innovative tests 05/21/2024
Cardio diagnostics holdings, inc. announces the availability of its clinical tests at family medicine specialists' retail healthcare clinic at walmart supercenter in round lake beach, illinois, that offers walk-in appointments seven days a week 05/13/2024
Cardio diagnostics announces publication of study showing that its precisionchd™ test could save health insurers over $113 million annually 04/29/2024
Exponential health partners with cardio diagnostics to elevate cardiovascular disease prevention in michigan 04/09/2024
Cardio diagnostics holdings, inc. enters into a nationwide telehealth agreement with navierre 04/04/2024
Cardio diagnostics holdings, inc. to showcase heartrisk and actionable clinical intelligence version 3 at the american college of cardiology's 73rd annual scientific session 03/14/2024
Cardio diagnostics holdings, inc. announces issuance of second u.s. patent for compositions and methods for detecting predisposition to cardiovascular disease 03/05/2024
Cardio diagnostics holdings, inc. expands heartrisk™ platform offering to diverse markets in conjunction with nationwide rollout 02/15/2024
Cardio diagnostics holdings, inc. expands partnership with family medicine specialists to bring its specialty cardiology tests to select walmart supercenters 02/07/2024
Houston-based restor longevity clinic to offer cardio diagnostics' ai-driven epigenetic-genetic heart disease tests 02/05/2024
Cardio diagnostics holdings, inc. accelerates cardiac care innovation with appointment of dr. vimal ramjee as strategic advisor 01/24/2024
Cardio diagnostics holdings, inc. announces the grant of a patent in india 01/08/2024
Correcting and replacing cardio diagnostics holdings, inc. unveils groundbreaking employer cardiovascular disease risk intelligence platform, heartrisk™ 01/04/2024
Cardio diagnostics holdings, inc. unveils groundbreaking employer cardiovascular disease risk intelligence platform, heartrisk™ 01/04/2024
American medical association (ama) grants cardio diagnostics a dedicated cpt pla reimbursement code for epi+gen chd, an ai-powered test for assessing the probability of a heart attack or coronary heart disease event 01/03/2024
American medical association (ama) grants cardio diagnostics holdings, inc.'s ai-powered coronary heart disease detection test, precisionchd, a dedicated cpt pla reimbursement code 01/02/2024
Cardio diagnostics holdings, inc. regains nasdaq minimum bid price requirement 12/06/2023
Correcting and replacing cardio diagnostics holdings, inc. convenes cardiovascular care & risk roundtable at the 42nd annual j.p. morgan healthcare conference 12/04/2023
Cardio diagnostics holdings, inc's convenes cardiovascular care & risk roundtable at the 42nd annual j.p. morgan healthcare conference 12/04/2023
American medical association is reviewing cardio diagnostics holdings, inc's integrated epigenetic-genetic cardiovascular medicine tests for cpt pla codes 11/28/2023
Cardio diagnostics holdings, inc. announces breakthrough in coronary heart disease detection with precisionchd test, published in the journal of the american heart association 11/20/2023
Family medicine specialists selects cardio diagnostics' epigenetic-genetic tests for assessing heart attack risk for its bluecross blueshield patients 11/07/2023
Cardio diagnostics holdings, inc receives innovative technology contract from vizient for its novel ai-driven precision heart disease tests – epi+gen chd & precisionchd 10/31/2023
Cardio diagnostics holdings, inc and aimil ltd join forces to introduce cardiovascular epigenetic technologies to india 10/17/2023
Cardio diagnostics holdings, inc launches new lab and fulfillment center, paving way for expanded testing capacity, reduced costs, reduced turnaround time and improved margins 10/12/2023
Cardio diagnostics publishes novel and scalable pathways to enhance global coronary heart disease care through precision epigenetics in epigenomics 09/20/2023
Cardio diagnostics holdings, inc partners with ascension borgess hospital's heart attack prevention clinic on coronary artery disease study 09/06/2023
Cardio diagnostics holdings, inc to participate in upcoming investor conferences 09/05/2023
Cardio diagnostics partners with frsteam of east kansas and west missouri to host first onsite heart disease fair in kansas using epigenetic-genetic technologies 08/18/2023
Cardio diagnostics holdings, inc announces expansion of ip portfolio in australia with notice of allowance of patent application 08/02/2023
Cardio diagnostics holdings, inc and riverrock medical partner to bring epigenetic-genetic heart disease testing to austin, texas 07/06/2023
Cardio diagnostics holdings, inc democratizes chd detection with nationwide launch of precisionchd™ 06/21/2023
Cardio diagnostics holdings, inc’s actionable clinical intelligencetm (aci) platform offers new epigenetic and genetic insights to inform coronary heart disease management 05/16/2023
Cardio diagnostics holdings, inc's actionable clinical intelligencetm (aci) platform offers new epigenetic and genetic insights to inform coronary heart disease management 05/16/2023
Cardio diagnostics holding, inc's actionable clinical intelligencetm (aci) platform offers new epigenetic and genetic insights to inform coronary heart disease management 05/16/2023
Transforming heart disease prevention for self-insured employers in oklahoma, missouri, kansas, and arkansas: a strategic alliance between connect clinic and cardio diagnostics 05/10/2023
Cardio diagnostics holdings, inc unveils the cardioinnovate360tm biopharma research system 05/04/2023
Juniper research awards cardio diagnostics holdings, inc future digital award for best digital diagnostics solution 04/26/2023
Cardio diagnostics holdings, inc to attend 22nd annual ahou conference 04/12/2023
Cardio diagnostics holdings, inc announces strategic engagement with lifespan.io to drive longevity & heart disease research and education 04/05/2023
Cardio diagnostics holdings, inc sponsors becker's hospital review 13th annual meeting 03/29/2023
Cardio diagnostics holdings, inc sponsors becker’s hospital review 13th annual meeting 03/29/2023
Cardio diagnostics holdings, inc announces financing agreement with yorkville advisors global, lp of up to $11.2 million 03/08/2023
Cardio diagnostics holdings, inc welcomes dr. damon broyles, md, as strategic advisor for precision cardiovascular medicine strategy 03/08/2023
Cardio diagnostics holdings inc announces expansion of ip portfolio with notice of allowance of patent application 03/02/2023
Cardio diagnostics holdings inc launches revolutionary blood test for early detection of coronary heart disease 02/28/2023
Cardio diagnostics holdings inc to debut precisionchd™ at the american college of cardiology's 72nd annual scientific session 02/22/2023
Cardio diagnostics holdings inc to debut precisionchd™ at the american college of cardiology’s 72nd annual scientific session 02/22/2023
Healing sanctuary clinic partners with cardio diagnostics holdings inc to offer the epi+gen chd test in their medical practice in idaho 01/05/2023
Cardio diagnostics holdings inc to attend 41st annual jp morgan healthcare conference 01/04/2023
Houston concierge medicine partners with cardio diagnostics to offer the epi+gen chd test in their executive health program 12/28/2022
Cardio diagnostics to present at the benchmark company's upcoming discovery one-on-one investor conference 11/21/2022
Cardio diagnostics to present at the benchmark company’s upcoming discovery one-on-one investor conference 11/21/2022
Cardio diagnostics named to fast company’s second annual list of the next big things in tech 11/17/2022
Cardio diagnostics holdings inc sponsors the illinois association of medicaid health plan’s annual conference 11/16/2022
Cardio diagnostics holdings inc sponsors the illinois association of medicaid health plan's annual conference 11/16/2022
Cardio diagnostics holdings inc ceo meesha dogan, accepted into forbes technology council 11/14/2022
Cardio diagnostics holdings inc sponsors becker's hospital review 11th annual meeting - the ceo + cfo roundtable 11/08/2022
Cardio diagnostics holdings inc sponsors becker’s hospital review 11th annual meeting - the ceo + cfo roundtable 11/08/2022
Cardio diagnostics holdings, inc. to list on nasdaq following successful business combination with mana capital acquisition corp. 10/26/2022

More Headlines

News
Reviewing ARCA biopharma (NASDAQ:ABIO) and Cardio Diagnostics (NASDAQ:CDIO) Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and ARCA biopharma (NASDAQ:ABIO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Profitability This table compares Cardio Diagnostics and ARCA biopharma’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Cardio Diagnostics -34,911.87% -415.33% -216.10% ARCA biopharma N/A -16.08% -15.51% Analyst Ratings This is a summary of current ratings and target prices for Cardio Diagnostics and ARCA biopharma, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 0 2 0 3.00 ARCA biopharma 0 0 0 0 N/A Cardio Diagnostics presently has a consensus price target of $1.35, indicating a potential upside of 84.93%. Given Cardio Diagnostics’ higher probable upside, equities analysts clearly believe Cardio Diagnostics is more favorable than ARCA biopharma. Volatility & Risk Cardio Diagnostics has a beta of 5.3, meaning that its share price is 430% more volatile than the S&P 500. Comparatively, ARCA biopharma has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Earnings & Valuation This table compares Cardio Diagnostics and ARCA biopharma’s revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardio Diagnostics $20,000.00 828.19 -$8.38 million N/A N/A ARCA biopharma N/A N/A -$5.34 million ($0.42) -7.93 ARCA biopharma has lower revenue, but higher earnings than Cardio Diagnostics. Institutional and Insider Ownership 8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 56.4% of ARCA biopharma shares are held by institutional investors. 30.0% of Cardio Diagnostics shares are held by insiders. Comparatively, 30.9% of ARCA biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Summary ARCA biopharma beats Cardio Diagnostics on 6 of the 10 factors compared between the two stocks. About Cardio Diagnostics (Get Free Report) Cardio Diagnostics Holdings, Inc., an artificial intelligence-powered precision cardiovascular medicine company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. The company was founded in 2017 and is headquartered in Chicago, Illinois. About ARCA biopharma (Get Free Report) ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. 05/20/2024
Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists' Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood tests are now available at FMS' newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois. 05/13/2024
Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually CHICAGO--(BUSINESS WIRE)--New study finds that Cardio Diagnostics' PrecisionCHD™ test could save health insurers over $113 Million per year. 04/29/2024
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan CHICAGO--(BUSINESS WIRE)--Exponential Health adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests marking a new era in personalized and preventive cardiac care. 04/09/2024
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre CHICAGO--(BUSINESS WIRE)--This collaboration aims to expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests. 04/04/2024
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology's 73rd Annual Scientific Session CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its HeartRisk and Actionable Clinical Intelligence platforms at the ACC's 73rd Annual Scientific Session. 03/14/2024
Cardio Diagnostics Holdings, Inc. Announces Issuance of Second U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has announced the issuance of its second U.S. patent. 03/05/2024
Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform. 02/15/2024
Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' AI-driven epigenetic-genetic blood tests will be available Q2 2024 inside the Walmart Supercenter in Round Lake Beach, Illinois. 02/07/2024
Houston-Based resTOR Longevity Clinic to Offer Cardio Diagnostics' AI-Driven Epigenetic-Genetic Heart Disease Tests CHICAGO--(BUSINESS WIRE)--resTOR Longevity Clinic will offer Cardio Diagnostics' blood-based epigenetic-genetic cardiovascular disease tests. 02/05/2024
Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. 01/24/2024
Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics announced that India's Patent Office has granted a patent to the University of Iowa Research Foundation under patent number 484488. 01/08/2024
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™ CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform. 01/04/2024
Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™ CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics has unveiled HeartRisk, the Company's groundbreaking employer cardiovascular disease risk intelligence platform. 01/04/2024
American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event CHICAGO--(BUSINESS WIRE)--The AMA has granted and assigned Cardio Diagnostics a dedicated CPT® PLA for the company's AI-driven CHD event risk assessment test, Epi+Gen CHD. 01/03/2024
American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.'s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that the AMA has assigned a dedicated CCPT® PLA) for the company's AI-driven CHD detection test, PrecisionCHD. 01/02/2024
Cardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. today announced it has regained Nasdaq minimum bid price requirement. 12/06/2023
CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference. 12/04/2023
Cardio Diagnostics Holdings, Inc's Convenes Cardiovascular Care & Risk Roundtable at the 42nd Annual J.P. Morgan Healthcare Conference CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will be presenting a roundtable session on cardiovascular care and risk at the 42nd Annual J.P. Morgan Healthcare Conference. 12/04/2023
American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc's Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the AMA CPT Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT PLA codes. 11/28/2023
Cardio Diagnostics shares rocket on validation of coronary heart disease detection test Cardio Diagnostics Holdings shares added more than 75% on Monday after positive results from a trial of the company's coronary heart disease (CHD) test PrecisionCHD were published in the Journal of the American Heart Association. The company noted that PrecisionCHD is a non-invasive and more accessible alternative to current CHD diagnosis tools being in the form of a blood test that uses AI and personalized genetic and epigenetic information to sensitively detect the presence of CHD. 11/20/2023
Why Is Cardio Diagnostics (CDIO) Stock Up 45% Today? Shares of cardiovascular medicine specialist Cardio Diagnostics (NASDAQ: CDIO ) are skyrocketing on Tuesday following the announcement of a key deal. Specifically, Vizient has awarded Cardio Diagnostics an “Innovation Technology” contract for its artificial intelligence (AI) driven molecular heart disease tests. 10/31/2023
Penny Stocks: The Importance of Liquidity and Volume Using liquidity and volume to make money with penny stocks The post Penny Stocks: The Importance of Liquidity and Volume appeared first on Penny Stocks to Buy, Picks, News and Information \| PennyStocks.com. 03/01/2023
Penny Stocks Vs. Blue Chips, Which Should You Trade? Are penny stocks better than blue chips? Here's why The post Penny Stocks Vs. 02/07/2023
Cardio Diagnostics to Present at the Benchmark Company's Upcoming Discovery One-on-One Investor Conference CHICAGO--( BUSINESS WIRE )--Cardio D iagnostics Holdings Inc (Nasdaq: CDIO) today announced it would be presenting at the Benchmark Company's 11th Annual Discovery One-on-One Investor Conference to be held Thursday, December 1st, 2022, at the New York Athletic Club in New York City. 11/21/2022

Unlock

cdio Ratings Summary

cdio Quant Ranking